Weekly channel feed

Am­gen to buy Hori­zon for $28B; Mer­ck, Mod­er­na tout can­cer vac­cine; FDA ap­proves sec­ond KRAS drug; and more

3 years ago

End­points hon­ors 20 women lead­ers; Ver­tex teams up with neigh­bor; Pfiz­er ri­val im­press­es; and more

3 years ago

Big week for Alzheimer’s da­ta; As­traZeneca buys cell ther­a­py start­up; Dig­i­tal ther­a­peu­tics hits a pay­er wall; and more

3 years ago

Big Phar­ma's Twit­ter ex­o­dus; Mer­ck wa­gers $1.35B on buy­out; $3.5M gene ther­a­py; and more

3 years ago

Alzheimer’s drug bites the dust; Re­struc­ture, re­struc­ture, re­struc­ture; Land­mark di­a­betes OK; and more

3 years ago

Bio­gen, Seagen lock in CEOs; 2022 so far — by the num­bers; Phar­ma on Twit­ter; Wave of biotech down­siz­ing ; and more

3 years ago

Lat­est news on pa­tient death in n-of-1 CRISPR tri­al; Good news for RSV; Vac­cine R&D rev­o­lu­tion; and more

3 years ago

Changes afoot at GSK; The first vic­tim of IRA?; As work halts, fam­i­lies be­hind gene ther­a­py seek con­trol; and more

3 years ago

Eli Lil­ly, Ab­b­Vie in M&A ac­tion; Gilead’s on­col­o­gy deal spree; FDA puts its foot down on Mak­e­na; and more

3 years ago

BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot tar­gets for M&A?; and more

3 years ago

Taste of M&A Mon­day; A spe­cial kind of lab; Biotech founder wins No­bel; Bio­Marin lay­offs; and more

3 years ago

Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

3 years ago

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

3 years ago

On heels of Lumakras da­ta drop, new KRAS idea emerges; Bris­tol My­ers, Ab­b­Vie, Ru­bius head­line busy week of re­struc­tur­ing; and more

3 years ago

Bris­tol My­ers Squibb scores TYK2 OK; ARCH backs mR­NA plat­form play; Il­lu­mi­na’s $8B co­nun­drum; Siz­ing up Al­ny­lam's win; and more

3 years ago

Lat­est news on FDA’s sec­ond look at Amy­lyx; Un­pack­ing Parkin­son’s R&D; Fiona Mar­shall takes over NI­BR from Jay Brad­ner; and more

3 years ago

Mod­er­na goes on the patent of­fen­sive; Pablo Legor­re­ta dou­bles down; Is a biotech re­cov­ery on the way?; and more

3 years ago

Roche's big Chi­na play; Mer­ck bets on mR­NA, again; Blue­bird's gene ther­a­py takes off; Bet­ter PhI­II? At a frac­tion of the cost?; and more

3 years ago

His­toric drug pric­ing re­forms pass; Pfiz­er ac­quires GBT; The long search for non-opi­oid pain drugs; and more

3 years ago

A $5B Pfiz­er buy­out? Am­gen, Gilead head­line M&A Thurs­day; Al­ny­lam's AT­TR sweep; An­drew Lo's rare dis­ease quest; and more

3 years ago

Big Phar­ma's in­creas­ing M&A en­thu­si­asm; Manchin, Schumer reach deal on drug pric­ing; Earn­ings re­caps; and more

3 years ago

Churn in FDA’s in­spec­tion unit; Roche’s chang­ing of the guard; Il­lu­mi­na on de­fense; NASH be­liev­er finds new chal­lenge; and more

3 years ago

No­var­tis' big PD-1 bet turns sour; $350M res­ur­rec­tion sto­ry; Con­tra­cep­tive for men heads to clin­ic; and more

3 years ago

Bis­pe­cif­ic M&A reach­es As­traZeneca; Count­down for Mer­ck­'s big bid; Biotech buy­out in sav­age times; and more

3 years ago
First page Previous page 3456789 Next page Last page
A service from the Financial Times